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Abstract
Background: Visceral obesity and insulin resistance are associated with a postprandial accumulation of atherogenic
chylomicron remnants that is difficult to modulate with lipid-lowering therapies. Dietary fish oil and exercise are
cardioprotective interventions that can significantly modify the metabolism of TAG-rich lipoproteins. In this study,
we investigated whether chronic exercise and fish oil act in combination to affect chylomicron metabolism in
obese men with moderate insulin resistance.
Methods: The single blind study tested the effect of fish oil, exercise and the combined treatments on fasting and
postprandial chylomicron metabolism. Twenty nine men with metabolic syndrome were randomly assigned to take
fish oil or placebo for four weeks, before undertaking an additional 12 week walking program. At baseline and at
the end of each treatment, subjects were tested for concentrations of fasting apo B48, plasma lipids and insulin.
Postprandial apo B48 and TAG kinetics were also determined following ingestion of a fat enriched meal.
Results: Combining fish oil and exercise resulted in a significant reduction in the fasting apo B48 concentration,
concomitant with attenuation of fasting TAG concentrations and the postprandial TAGIAUC response (p < 0.05). Fish
oil by itself reduced the postprandial TAG response (p < 0.05) but not postprandial apo B48 kinetics. Individual
treatments of fish oil and exercise did not correspond with improvements in fasting plasma TAG and apo B48.
Conclusion: Fish oil was shown to independently improve plasma TAG homeostasis but did not resolve hyper-
chylomicronaemia. Instead, combining fish oil with chronic exercise reduced the plasma concentration of pro-
atherogenic chylomicron remnants; in addition it reduced the fasting and postprandial TAG response in viscerally
obese insulin resistant subjects.
Background
The problem of obesity has become high priority globally.
Nearly two thirds of deaths and 46% of the worldwide bur-
den of disease are due to non-communicable, obesity-
associated diseases [1]. In 2008 more than one third of the
world’s adults were overweight, which is a doubling of the
prevalence since 1980 [2]. The phenotype of visceral obe-
sity is associated with a cluster of related conditions called
metabolic syndrome (MetS), which encompasses both
lipid and non-lipid related disorders. These disorders
include insulin resistance, pro-inflammatory and pro-
thrombotic states and the emergence of an atherogenic
lipoprotein profile. Amongst the latter, changes to post-
prandial lipoprotein kinetics and an increased fasting chy-
lomicron remnant concentration are commonly reported
and may contribute to increased coronary artery disease
risk in viscerally obese subjects [3,4].
In MetS, higher rates of chylomicron production
coupled with reduced clearance by high affinity pathways
(i.e. the LDL receptor) can contribute to an accumulation
of pro-atherogenic chylomicron remnants in plasma
[5-9]. Moreover, several studies from our laboratory
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insulin resistant obese subjects is more difficult to
achieve than for hepatically derived lipoproteins. We
found that an acute insulin infusion for six hours post-
prandially substantially lowered the apo B100 area under
the curve but not the chylomicron apo B48 response
[10]. In another study, chronically enhancing insulin sen-
sitivity with the provision of metformin, or a peroxisome
proliferator receptor antagonist (rosiglitazone) had no
effect on fasting apo B48, or postprandial hyperchylomi-
cronaemia [11]. Likewise, a 10 kg weight reduction fol-
lowing moderate energy restriction did not improve
chylomicron homeostasis in a similar cohort [12]. Simi-
larly, in dyslipidaemic diabetic subjects, others have
found that the fasting apo B48 concentration was not sig-
nificantly lowered by fluvastatin alone, but when fish oil
was concurrently administered, the change was signifi-
cant [13]. Based on these findings, we suggest that inter-
ventions designed to regulate lipoprotein kinetics may
need to be more aggressive to modulate the chylomicron
fraction, compared to interventions that reduce hepati-
cally derived apo B.
There is interest in unsaturated fatty acids (FA), parti-
cularly the n-3 FA from fish oil in lipoprotein metabolism
since they suppress secretion of apo B100 by the liver and
promote plasma clearance via high affinity pathways
[14-16]. Evidence from animal experiments shows that
the chylomicron secretion rate may be up-regulated by
habituating to a higher fat diet [17], and the type of fat
can also influence chylomicron secretion [18] or fasting
concentrations [19]. The n-3 FA could result in secretion
of fewer chylomicrons because they significantly suppress
intestinal TAG production in several experimental mod-
els of the intestine [20,21]. Furthermore receptor-
mediated uptake of chylomicron remnants is significantly
enhanced if the particles are enriched in n-3 FA [22].
However, how these n-3 related mechanisms translate
into changes in human chylomicron homeostasis is yet to
be resolved [23].
Human studies by Gill and colleagues [24] also suggest
that postprandial lipoprotein metabolism is improved by
exercise in otherwise healthy subjects. They reported in
middle-aged men that a single bout of treadmill walking
substantially enhanced apo B100 metabolism of the
VLDL1 fraction concomitant with a slight reduction in
postprandial apo B48 concentration. It is reasonable to
suggest that a more sustained exercise regimen will have
a greater effect on apo B48 metabolism due to progres-
sive improvements in muscle vascularisation and greater
conversion of TAG-rich lipoproteins to the high- uptake
remnant form [25]. Improvements in insulin sensitivity
associated with exercise may also stimulate high affinity
remnant clearance pathways that are sufficient to pro-
mote chylomicron remnant clearance. However, the
effects of a chronic exercise regimen, specifically on post-
prandial apo B48 metabolism in insulin resistant subjects
are not reported.
Therefore we intended to investigate the combined
interventions of fish oil and exercise on chylomicron
metabolism in viscerally obese, insulin resistant men
using a chronic study design. The protocol aimed to
achieve an exercise volume consistent with optimising
metabolic effects [26], and participation rates. The sec-
ond part of our hypothesis is based on evidence that the
n-3 FA have potential to modulate lipoprotein kinetics,
at the level of clearance and possibly also secretion.
Furthermore acute exercise may also alter apo B48 con-
centrations [24], but the long-term effect of exercise
combined with fish oil, on chylomicron metabolism has
not been previously explored in these subjects.
Methods
Participants and protocol
Sedentary overweight or obese men aged 32 to 65 years
were recruited based on having MetS, a low physical
activity level and absence of dietary oil supplementation
or fish consumption. MetS was classified as having three
or more risk factors specified by the ATP III guidelines
[27]. Subjects had a BMI > 27 kg/m
2 and or umbilical cir-
cumference > 102 cm; dyslipidaemia (fasting TAG > 1.69
mmol/L and or HDL cholesterol < 1.03 mmol/L) and
fasting blood glucose concentration > 6.1 mmol/L. All
subjects gave written consent and the study was approved
by Curtin University’s Human Research Ethics
Committee.
Exclusion criteria included smoking and major sys-
temic illness, incorporating gastrointestinal, liver, kidney,
diabetes, thyroid, other hormonal diseases and alcohol-
ism. Subjects taking medications that interfere with lipid
metabolism and gastrointestinal function were excluded.
Twenty nine subjects participated in the study and were
randomised to take either the placebo or fish oil. The fish
oil was taken as supplements (Bio-Organics Mega eicosa-
pentaenoic acid (EPA)/docosahexaenoic acid (DHA) cap-
sules, Mayne Group Ltd, Carina, Australia) and the
placebo was a 500 mg glucose/starch tablet purpose-made
by the School of Pharmacy (Curtin University, Bentley,
Australia). Subjects were blinded to the treatment type
and were not able to see the alternate treatment during
the study (i.e. the difference between the capsules and
tablets). Between weeks 0 and 16 subjects consumed four
fish oil capsules (providing a total of 1000 mg EPA and
700 mg DHA) or four placebo tablets (2000 mg glucose/
starch) per day with meals. Fatty acid composition of the
fish oil capsules was confirmed using gas chromatography
following esterification with BF3-methanol [28]. The initial
fish oil intervention period was four weeks since
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three or four weeks [17,29].
Following the initial four week run-in period with fish
oil or placebo, exercise was introduced in combination to
both groups. This combined intervention phase was
maintained for an additional 12 weeks. The exercise pro-
tocol consisted of supervised walking sessions tailored to
the subjects’ fitness levels. Initially subjects attended a
minimum of two sessions per week, which was increased
as their fitness increased to 3-5 sessions per week during
their final three weeks of intervention. Heart rate (HR)
was determined by short range telemetry and moderate
intensity exercise was determined as 50 to 65% of the
subject’s training HR [30]. In each hour-long session sub-
jects expended approximately 1990 kJ of energy. Prior to
and at the end of the exercise intervention, subjects
underwent a physical work capacity test at 75% of their
age predicted maximum HR to determine change to their
physical fitness. Apart from the exercise intervention,
subjects were asked to maintain their usual physical
activity levels throughout the study.
Outcome measures were tested at weeks 0, 4 and 16
where subjects underwent fasting and postprandial assess-
ment. Subjects were instructed to maintain their usual diet
throughout the study and this was checked fortnightly by a
trained interviewer using food frequency questionnaires.
For three days prior to each testing day the diet was stan-
dardised. Standard diet formulation was based on the aver-
age habitual intake of the subjects determined by three-day
food records, as well as data from the Australian National
Nutrition Survey [31]. Nutrient composition of the stan-
dard diet is shown in Table 1; subjects modified this
according to their own energy needs and replicated the
same diet before each postprandial test.
Compliance to intervention
Compliance with the fish oil intervention was assessed
by capsule count and subjects who forgot to take their
capsules were asked to take them with their following
dose. The number of walks completed was similar
between groups (37 FOX vs. 40 PX, p = 0.067). Eighty
nine percent of the subjects attended > 88% of their
walking sessions. On average, subjects walked 38.5 h
over 12 weeks and all attended a minimum of three ses-
sions per week in the final three weeks of the interven-
tion. The average percentage HR reserve attained during
the exercise was 53.4 ± 1.31% and within the definition
of moderate intensity [30]. A 31% increase in physical
work capacity was reported followed the exercise inter-
vention (0.95 v. 1.21 W/kg) and this was similar for sub-
jects who received the FO or placebo.
Postprandial and laboratory assessments
Subjects fasted overnight and at 07.00 hours reported to
the clinical room at Curtin University for the postprandial
test. Anthropometry was conducted; height was measured
using a stadiometer fixed to the wall and weight was deter-
mined with the subject wearing light clothing and no
shoes. Waist circumference was measured at the level of
the umbilicus using a standard metal anthropometry tape.
Venous blood was collected before subjects consumed a
moderate-fat test meal (100 g Uncle Toby’s Sports Plus™,
150 g skim milk, 30 g skim milk powder and 100 g whip-
ping cream, providing 3688 kJ, 44 g of fat, 94.1 g of CHO
and 27.4 g of protein). Fasting blood was analysed for apo
B48, lipids (TAG, total-, HDL- and LDL- cholesterol), glu-
cose and insulin. Postprandial samples were collected at 2,
3, 4, 5, 7 and 9 hours in the post-absorptive state and were
measured for apo B48 and lipid concentrations. Through-
out the day subjects were confined to resting and were
given no further food or drink apart from ad libitum water.
Plasma apo B48 was quantified using a Western blot-
ting/enhanced chemiluminescent procedure as previously
described [11]. The mean intra- and inter-assay coeffi-
cients of variation for apo B48 were each less than 4%.
Plasma TAG and cholesterol concentrations were deter-
mined by enzymatic colourimetric kits (Randox Labora-
tories, Antrim, UK) according to the manufacturers’
instructions. Glucose concentration was determined from
serum after enzymatic oxidation in the presence of glucose
oxidase according to the manufacturer (Randox Labora-
tories, Antrim, UK). Samples were analysed in triplicate
then read photometrically using a Bio-Rad 550 microplate
reader.
The insulin assay consisted of a solid-phase, two site
chemiluminescent immunometric assay performed on the
Biomediq DPC Immulite 2000 analyser (Clinipath Pathol-
ogy, Perth, Australia). Estimation of insulin resistance was
determined by calculation of HOMA score as described by
Matthews et al. [32,33].
Baseline data are reported as BP for the placebo group
and BF for the fish oil group at week 0. Week four data
Table 1 Daily nutrient composition of the standard diet
Energy (kJ) 11 000
Protein (g) 108
Carbohydrate (g) 361
Fat (g) 91
SFA (g) 39
MUFA (g) 35
PUFA (g) 17
Cholesterol (mg) 184
Fibre (g) 42
Table 1 shows the average daily nutrient composition of the diet that subjects
were provided with. Subjects modified the amounts of these foods according
to their own energy requirements and this diet was replicated before each
postprandial test.
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for those on placebo and exercise and FOX for fish oil
plus exercise. Summary measures of the postprandial
response are reported as the incremental area under the
concentration-v.-time curve (IAUC). The IAUC was calcu-
lated by subtracting the area below the baseline concen-
tration from the total AUC using the trapezium rule [34].
Statistical analysis
Within-group changes were compared using paired t-
tests and one-way repeated measures ANOVA with
Bonferoni’s post hoc analysis. The difference between
groups was assessed using univariate ANOVA adjusting
for age and results at week 0. Statistics were performed
using IBM SPSS 19.0 and results were considered signif-
icant at a 5% level (two-tailed). Data are presented as
mean values with their standard errors.
Results
Twenty nine subjects were initially recruited. To begin
with 16 subjects participated in the fish oil group and
after week four, two subjects withdrew for personal rea-
sons. Data for BF and FO are thus reported for 16 sub-
jects and 14 subjects for the FOX intervention. Thirteen
subjects completed the entire intervention for the pla-
cebo group (BP, P and PX).
Baseline measurements indicate that the subject char-
acteristics were generally similar between the rando-
mised control and intervention groups, although the
latter were modestly younger (p = 0.011) (Table 2). The
baseline HOMA score suggested insulin resistance,
whilst plasma TAG and HDL cholesterol concentrations
indicated dyslipidaemia [27].
Fasting and postprandial lipid and insulin sensitivity
results
Fish oil supplementation provided at 1000 mg EPA and
7 0 0m gD H Ap e rd a yf o rf o u rw eeks in insulin resistant
men did not lower fasting plasma TAG, however post-
prandial lipaemia expressed as TAGIAUC was reduced by
almost 20% compared to baseline (p = 0.020) and 25% less
than subjects given placebo capsules (p = 0.025) (Table 2,
Figure 1). There was no difference in fasting TAG concen-
tration or TAGIAUC in subjects given placebo. The
improvement in TAGIAUC in FO supplemented subjects
occurred despite a higher blood glucose (p = 0.034) and
HOMA score (p = 0.034). Total fasting cholesterol
remained unchanged in the FO group, however LDL-cho-
lesterol concentration was increased by approximately 8%
compared to baseline (p = 0.049) (Table 2). There was no
significant difference in total- or LDL-cholesterol concen-
trations between subjects given FO or placebo.
Introduction of exercise concomitant with FO supple-
mentation had a substantial lowering effect on fasting
plasma TAG concentration (p = 0.026) and TAGIAUC
(p = 0.004) that was not apparent with the provision of
exercise without FO supplementation. In the FOX group
of subjects, fasting TAG concentration was reduced by
21% after exercise (p = 0.026), whereas TAGIAUC was
reduced 36% compared to baseline (p = 0.025) and by
22% compared to FO supplementation alone (p = 0.004)
(Table 2). Exercise did not reduce total- or LDL-
Table 2 Results for baseline, week 4 and week 16
Control group Fish oil group
Week 0 (BP)
(n = 13)
Week 4 (P)
(n = 13)
Week 16 (PX)
(n = 13)
Week 0 (BF)
(n = 16)
Week 4 (FO)
(n = 14)
Week 16 (FOX)
(n = 14)
Age (y) 56.2 ± 1.3 49.2 ± 2.0
d
BMI (kg/m
2) 31.9 ± 1.3 31.9 ± 1.2 31.6 ± 1.2 32.5 ± 0.8 32.6 ± 0.8 32.3 ± 0.9
UC (cm) 112.8 ± 2.5 111.6 ± 2.2 111.4 ± 2.7 110.1 ± 1.8 108.9 ± 1.7 108.2 ± 1.8
Fasting results
Fasting glucose (mmol/L) 6.49 ± 0.62 6.54 ± 0.73 6.38 ± 0.54 6.50 ± 0.15 6.89 ± 0.88
d 6.66 ± 0.87
HOMA 3.37 ± 0.42 3.35 ± 0.40 3.09 ± 0.38 3.60 ± 0.34 4.29 ± 0.50
a 3.27 ± 0.35
c
Fasting TAG (mmol/L) 1.85 ± 0.24 1.97 ± 0.27 1.85 ± 0.21 1.69 ± 0.15 1.67 ± 0.14 1.31 ± 0.08
b, c, d
Fasting Total-C (mmol/L) 5.36 ± 0.25 5.60 ± 0.19 5.41 ± 0.29 5.25 ± 0.16 5.40 ± 0.17 5.24 ± 0.20
Fasting LDL-C (mmol/L) 3.55 ± 0.23 3.67 ± 0.16 3.49 ± 0.20 3.39 ± 0.17 3.68 ± 0.17
a 3.60 ± 0.20
Fasting HDL-C (mmol/L) 0.92 ± 0.05 1.02 ± 0.04
a 1.06 ± 0.05
b 1.00 ± 0.03 0.96 ± 0.04 1.04 ± 0.04
c
Fasting apo B-48 (mg/L) 10.96 ± 1.20 11.12 ± 1.18 10.56 ± 1.11 9.91 ± 0.63 10.17 ± 0.92 8.51 ± 0.82
b
Postprandial results
TAG IAUC (mmol/L/9 h) 9.0 ± 0.8 10.1 ± 1.1 9.0 ± 1.0 9.4 ± 1.0 7.7 ± 1.0
a, d 6.0 ± 0.8
b, c, d
Apo B48 IAUC (mg/L/9 h) 13.2 ± 2.2 12.5 ± 2.0 14.4 ± 2.0 15.1 ± 2.0 13.4 ± 2.4 14.8 ± 1.9
Results are mean ± SE.
Within group differences as indicated; week 4 v. week 0
a; week 16 v. week 0
b; week 16 v. 4
c. Between group differences placebo v. FO same week
d
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terol concentration to a similar extent in both groups of
s u b j e c t s( P Xv s .P ,p=0 . 0 2 5 ;F O Xv s .F O ,p=0 . 0 0 1 ) .
Moreover, the addition of exercise completely abolished
the heightened HOMA score induced by FO supplemen-
tation alone (p = 0.020).
Fasting apo B48 and postprandial apo B48
Apo B48 is an unequivocal marker of chylomicron meta-
bolism and was used to differentiate between the putative
lipid modulating effects of FO and exercise versus that of
chylomicron kinetics. Of the interventions investigated,
only the combination of FOX attenuated the fasting apo
B 4 8c o n c e n t r a t i o n( p=0 . 0 4 9 ) .T h e r ew a sn os i g n i f i c a n t
effect of FO, PX or FOX on the postprandial chylomicron
apo B48IAUC response (Figure 2, Table 2).
Discussion
This paper reports on the effects of fish oil and chronic
exercise on chylomicron and lipid metabolism in men
with insulin resistance. Subjects taking fish oil showed a
reduced postprandial TAG response to the moderate fat-
containing meal after four weeks. Following the 12 week
walking program the fish oil group exhibited an even
greater postprandial TAG reduction, and a lower fasting
TAG concentration. The combined interventions did not
decrease the total or LDL cholesterol concentrations,
however by the end of the treatment both groups had
increased HDL-cholesterol concentrations compared to
baseline and each individual treatment at week four.
Most significantly our findings suggest that the combined
effect of the chronic exercise and fish oil was sufficient to
alter the basal metabolism of chylomicrons in these visc-
erally obese subjects.
The reduction of fasting TAG that occurred when the
interventions were combined corresponds with sugges-
tions in the literature that both exercise and fish oil
could individually reduce VLDL production [15,35],
mainly by suppressing hepatic lipogenesis. The combined
interventions also lowered the postprandial TAG
response. A reduction in fasting VLDL production could
have facilitated the lower postprandial TAGIAUC response
as a result of less competition with the exogenous TAG
for lipid clearance mechanisms. The lipaemic reduction
is also likely because of increased lipoprotein lipase activ-
ity in adipose tissue following fish oil [36] or in the leg
muscle after exercise [24]. As a result of chronic training
adaption, exercise is also suggested to promote lipid
clearance by increasing capillary vascularisation [37,38],
as was expected after 12 weeks of regular walking. Since
chylomicrons are the preferred substrate for lipoprotein
lipase, it is likely that our combined interventions
affected chylomicron delipidation in the early postpran-
dial phase and then the VLDL that predominates later in
the postprandial excursion [5]. Hydrolysis from both
Figure 1 Postprandial TAG measured at weeks 0, 4 and 16. BP, placebo group at baseline; P, placebo group at 4 weeks; PX, placebo plus 12
weeks of exercise. BF, fish oil group at baseline; FO, four weeks of fish oil; FOX fish oil plus 12 weeks of exercise.
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mechanism in the postprandial TAG reduction.
The effect of fish oil significantly lowered the
TAGIAUC response even without exercise. In animals
and humans, fish oil accelerates catabolism of VLDL to
LDL [36] through enhancing blood circulation to capil-
lary lipases, lipase binding or expression [39-41]. Such
catabolic changes correspond to our results of an
increased LDL cholesterol concentration initially after
four weeks of fish oil. Others reporting similar findings
a f t e rf o u ra n ds i xw e e k so ff i sh oil have proposed that
this increase might be in the LDL1 fraction rather the
small dense particles [42,43] which suggests that mea-
suring plasma lipids following fish oil in the longer term
(i.e. chronic interventions) may be more physiological
useful than shorter studies. Interestingly we also
reported increases in glucose concentration and HOMA
score with the four weeks of fish oil, findings which are
also reported in the literature. Woodman et al. [44]
measured interim blood glucose concentrations at three
weeks during their six week n-3 FA trial and discuss a
transient adverse trend in glycaemic control, which was
corrected by the end of the trial. As did Mori and col-
leagues [45], who suggest that the variability in the
effect of fish oil on glycaemic control may arise from
varying degrees of insulin sensitivity between subjects
and the presence of other disorders including
hypertension and obesity. By the time our subjects had
undergone the additional exercise at week 16, the fish
oil-associated HOMA increase was abolished, consistent
with earlier findings [46]. However based on the present
results, it would be prudent to suggest that insulin resis-
tant patients monitor their glycaemic control when
commencing fish oil supplements, and incorporate regu-
lar, moderate intensity exercise into their lifestyle.
Our key finding was that fish oil plus chronic exercise
did modulate the basal metabolism of apo B48, a finding
not reported elsewhere in the literature. This finding is
important since chylomicron homeostasis is more diffi-
cult to modulate than that of hepatic lipoproteins [25].
The fasting apo B48 concentration represents the differ-
ence between the constitutive secretion rate and the
clearance rate of the lipid-poor remnants. Suggestions
from cell, animal and human studies is that fish oil and
exercise could modulate both the clearance of apo B48
remnants [22,47-52], and also play a role in reducing
apo B48 secretion [53].
Our results have shown that a combined fish oil and
exercise intervention may be effective in reducing fasting
apo B48 in otherwise free-living, insulin resistant sub-
jects. The interaction between fish oil and exercise may
be hinged on the fact that our subjects were insulin
resistant throughout the study. Insulin resistance may
have contributed to an over-secretion of intestinal apo B
Figure 2 Postprandial apo B48 measured at weeks 0, 4 and 16. BP, placebo group at baseline; P, placebo group at 4 weeks; PX, placebo
plus 12 weeks of exercise. BF, fish oil group at baseline; FO, four weeks of fish oil; FOX fish oil plus 12 weeks of exercise.
Slivkoff-Clark et al. Nutrition & Metabolism 2012, 9:9
http://www.nutritionandmetabolism.com/content/9/1/9
Page 6 of 9[5] as well as compromised the receptor-mediated
uptake of apo B48 in our subjects. Another feature of
insulin resistance is the association with inflammatory
markers (e.g. C-reactive protein, prostaglandin PGE2,
pro-inflammatory cytokines) [54] and high oxidative
stress [55]. Liver cell culture studies suggest that this
stress may impact chylomicron remnant uptake [52].
Therefore it is plausible that by improving our subjects’
oxidative status through 12 weeks of regular exercise
[56,57], and long-term fish oil [58-61] we may have
somewhat corrected the defective uptake of chylomicron
remnants by the liver in separate but related mechan-
isms. A further suggestion from cell culture studies is
that when the oxidative status of the liver was improved,
the degree of improvement to remnant uptake was even
more enhanced when remnants were enriched with n-3
FA [52]. This suggestion might allude to why in our
human study the basal apo B48 concentration was only
lower when the fish oil and chronic exercise were added
together.
We therefore conclude that an effective therapeutic
strategy for the chylomicronaemia in subjects with MetS
is the combination of chronic, regular exercise and a
relatively low dose of fish oil. We also note that these
benefits occurred even without insulin resistance being
completely normalised. The mechanisms through which
these two interventions work are likely to be different,
which may be why they were efficacious only when used
in combination. While our study was not intended to
test the mechanisms, further investigation is warranted
to decipher the reasons that chronic exercise and fish
oil reduce basal apo B48 concentration in insulin resis-
tant men.
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